SLC5A2 and type 2 diabetes mellitus: Sodium-glucose cotransporter-2 (SGLT2) inhibitors, initially developed for T2DM management, have emerged as a promising therapeutic class for MASLD due to their pleiotropic metabolic and cardiovascular benefits [13].